Avis de sécurité sur les produits de santé
Avis de sécurité sur les produits de santé au Canada et d’autres pays.
Pays
* Les informations sont disponibles en anglais seulement.
⇡ Canada
Santé Canada – Rappels et avis de sécurité
Autres ressources
- InfoVigilance sur les produits de santé
- Quoi de neuf – MedEffet Canada
- Bulletins de l’ISMP Canada
- Médicaments sécuritaires (en anglais seulement)
- Registre des médicaments et des produits de santé
- Signaler un effet secondaire
- Capsules Rx – Avis de Santé Canada (connection requise)
⇡ États-Unis
⇡ France
⇡ Royaume-Uni
- Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measureAdvice for healthcare professionals regarding the withdrawal of pholcodine-containing medicines from the market.
- New recommendations following a recent clinical trial which found that in patients with type 1 hepatorenal syndrome terlipressin may cause serious or fatal respiratory failure at a frequency higher than previously known, and…
- Recent information relating to COVID-19 vaccines and medicines that has been published since the February 2023 issue of Drug Safety Update, up to 21 March 2023.
- A summary of recent letters and notifications sent to healthcare professionals about medicines.
- Recent information relating to COVID-19 vaccines and medicines that has been published since the January 2023 issue of Drug Safety Update, up to 21 February 2023.
- A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
- Prescribers and dispensers should use caution if switching patients between different metolazone preparations as the rate and extent of absorption of metolazone are formulation dependent. This can impact the bioavailability …
- Premature puberty and genital enlargement have been reported in children who were in close physical contact with an adult using topical testosterone and who were repeatedly accidentally exposed to this medicine. To reduce th…
- We ask healthcare professionals to be vigilant to adverse incidents involving software, apps, and artificial intelligence (AI) as medical devices and to report incidents to us via the Yellow Card scheme.
- Recent information relating to COVID-19 vaccines and medicines that has been published since the December 2022 issue of Drug Safety Update, up to 23 January 2022.
⇡ Nouvelle-Zélande
- Update – Abnormal uterine bleeding and oral anticoagulants (blood thinners)
- New legislation about medicines that can impair driving
- Reports of pericarditis following mpox vaccination
- Goserelin (Teva) 3.6mg and 10.8 mg implants and reports of issues when administering this medicine
- Myocarditis and pericarditis have been reported with Nuvaxovid (Novavax COVID-19 Vaccine)
- Recall of KetoSens Test Strips – batch UJ03PBXNG
- Update – Possible risk of vasculitis with vildagliptin products (Galvus, Galvumet)
- Abnormal uterine bleeding and oral anticoagulants (blood thinners)
- Medsafe is publishing a warning that the product Nhan Sam Tuyet Lien Truy Phong Hoan should not be consumed
- Accuretic found to contain nitrosamines